#What Happened with Dave Perrill's Shares?
Dave Perrill, a key director at HIVE Digital Technologies, executed a sale of 175,000 common shares on June 19, earning approximately $820,750 at an average price of $4.69 per share. Following this transaction, he now holds no direct common shares of the company but retains 325,000 unvested restricted share units, scheduled to become his by March 2027. It is worth noting that other directors at HIVE have undertaken similar sales recently, suggesting this might reflect a common operational pattern rather than a singular event.
#How Did the Sale Work?
The shares Perrill sold were not acquired via the open market; they came from restricted share units that vested into common shares on May 7. These units were part of his compensation package and became his assets approximately six weeks before they were sold. Perrill opted to liquidate these shares into cash rather than hold onto them.
#What’s Driving HIVE’s Business Performance?
HIVE Digital Technologies reported substantial fiscal growth, with a revenue of $297.8 million for the fiscal year 2026. This marks a remarkable increase of 158% compared to the previous year, mainly fueled by their mining operations and the rising segment focusing on high-performance computing, specifically in AI infrastructure.
Additionally, on June 25-26, HIVE announced a significant upsized private offering of $115 million in 0% exchangeable senior notes due in 2031. The proceeds are designated for advancing AI and GPU cloud initiatives, further solidifying HIVE's commitment to growth in these sectors.
#What Should Investors Take Away from This?
Investors should note that Perrill's decision to hold onto his 325,000 unvested RSUs rather than expedite or hedge them suggests confidence in HIVE’s future. The fact that HIVE is experiencing a 158% year-over-year growth and successfully raising capital without interest for its AI projects is a strong indicator of its growth trajectory. Furthermore, with shares trading heavily up by nearly 177% over the past year, HIVE appears to be in an advantageous position, making it an intriguing option for investors assessing potential growth stocks.